Clinical Trial Update: Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for abiraterone acetate plus prednisone in chemo-naive metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone Acetate Plus Prednisone (abiraterone acetate)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED